logo-loader
viewMedicenna

Medicenna Therapeutics completes Phase 2B study on cancer drug mdna55

Medicenna Therapeutics (TSE: MDNA) CFO Elizabeth Williams joined Steve Darling from Proactive Vancouver at LD MIcrocap Conference in Vancouver with news about their lead drug mdma55. Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective and first in class Empowered Cytokines. 


 

Quick facts: Medicenna

Price: 5.87 CAD

TSX:MDNA
Market: TSX
Market Cap: $286.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pacific Empire Minerals sees strong results from sampling at Jean Marie...

Pacific Empire Minerals Corp (CVE: PEMC-OTCQB: PEMSF) CEO Brad Peters joined Steve Darling from Proactive Vancouver to shares some results from their Jean Marie project. Peters saying those results were from rock chip and grab samples. Peters talked more about Jean Marie and the potential for...

1 hour, 16 minutes ago

2 min read